ASH 2016 | Advances in low grade lymphoma over the past 40 years
Nathan Fowler, MD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the history of chemotherapy and advances in low grade lymphoma. Dr Fowler explains that in the last 30-40 years, we have seen an improvement in survival of patients with low grade lymphoma every decade and today, most patients will never die of follicular lymphoma. He points out that we now have to pay attention to long-term toxicity and the financial burden associated with the new drug regimens. Dr Fowler also mentions how new regimens such as lenalidomide, rituximab, and ibrutinib may ultimately lead to a cure or prolonged remissions.
Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up